Structure-Activity Relationships of Inactive-Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric

Surbhi P Chitnis1, Florian Wittlinger2,3, Mareike Möllers2

  • 1Department of Chemistry, The State University of New York at Buffalo, Buffalo, New York, USA.

Archiv Der Pharmazie
|July 16, 2025
PubMed

Insights

Next-generation EGFR inhibitors targeting non-small cell lung cancer (NSCLC) were developed by exploring ATP-site imidazole scaffolds. Novel back pocket binding groups show high potency, offering new directions for kinase inhibitor discovery.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase is a key target in non-small cell lung cancer (NSCLC).
  • Emergence of resistance mutations necessitates development of next-generation EGFR inhibitors.
  • Previous research has neglected ATP-competitive inhibitors targeting the EGFR back pocket.

Purpose of the Study:

  • To investigate the incorporation of functional groups into an ATP-site imidazole scaffold for EGFR tyrosine kinase inhibitors (TKIs).
  • To identify novel binding strategies for overcoming resistance mutations in EGFR-positive NSCLC.

Main Methods:

  • Systematic survey of functional groups extending into the EGFR back pocket.
  • Design and synthesis of imidazole-based scaffolds with diverse substituents.
  • Evaluation of inhibitor potency and structural analysis of binding interactions.

Main Results:

  • Meta-substituted amide linkers with fluorine and/or hydroxy groups in the back pocket phenyl demonstrated highest potency.
  • Identification of specific binding interactions between functional groups and the EGFR back pocket.
  • Demonstrated feasibility of targeting the EGFR back pocket with novel imidazole scaffolds.

Conclusions:

  • Novel imidazole-based scaffolds with specific back pocket interactions represent a promising strategy for next-generation EGFR TKIs.
  • These findings provide new directions for the discovery and optimization of kinase inhibitors targeting inactive conformations.
  • The developed inhibitors show potential for overcoming resistance in EGFR-mutated NSCLC.

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
59.1K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K